Shares of Amgen, Inc. (NASDAQ:AMGN) have received an average recommendation of “Hold” from the twenty-one research firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $209.94.
A number of brokerages recently commented on AMGN. Zacks Investment Research cut Amgen from a “buy” rating to a “hold” rating in a research note on Friday, April 5th. Mizuho set a $208.00 price objective on Amgen and gave the stock a “buy” rating in a research note on Friday, April 12th. BidaskClub cut Amgen from a “hold” rating to a “sell” rating in a research note on Tuesday, April 23rd. Finally, Cowen reaffirmed a “buy” rating and set a $229.00 price objective on shares of Amgen in a research note on Wednesday.
NASDAQ AMGN opened at $176.50 on Friday. The firm has a market capitalization of $110.45 billion, a PE ratio of 12.26, a PEG ratio of 2.20 and a beta of 1.15. Amgen has a 52 week low of $165.22 and a 52 week high of $210.19. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36.
Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, April 30th. The medical research company reported $3.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.45 by $0.11. The company had revenue of $5.56 billion during the quarter, compared to analysts’ expectations of $5.55 billion. Amgen had a return on equity of 67.08% and a net margin of 34.00%. The business’s revenue for the quarter was up .1% on a year-over-year basis. During the same period last year, the firm earned $3.47 EPS. As a group, equities research analysts expect that Amgen will post 13.95 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a dividend of $1.45 per share. The ex-dividend date is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.29%. Amgen’s dividend payout ratio is presently 40.28%.
In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $193.18, for a total transaction of $386,360.00. Following the transaction, the director now directly owns 15,092 shares in the company, valued at $2,915,472.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink . Over the last quarter, insiders have sold 6,000 shares of company stock worth $1,144,120. Corporate insiders own 0.25% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Mackey Komara & Dankovich LLC bought a new position in Amgen during the first quarter worth about $25,000. Ruggie Capital Group lifted its holdings in shares of Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 101 shares in the last quarter. Arlington Partners LLC lifted its holdings in shares of Amgen by 86.7% in the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 65 shares in the last quarter. Capital Financial Planning LLC bought a new stake in shares of Amgen in the fourth quarter valued at about $27,000. Finally, Massey Quick Simon & CO. LLC lifted its holdings in shares of Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 80.00% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. Analyst Recommendations for Amgen (NASDAQ:AMGN) Receive News & Ratings for Amgen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at Amgen, Inc. (AMGN) Given Consensus Rating of “Hold” by Brokerages